Immix Biopharma (IMMX) Income Statement (2021 - 2026)
Income Statement report data from Mar 31, 2021 to Mar 31, 2026 for Immix Biopharma (IMMX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 8, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||||||||||
Total Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 20M | - | - | - | - | - | - | - |
Operating Expenses | |||||||||||||||||||||
Research And Development | 5.98M | - | 4.58M (+15.37%) | 3.97M (+100.51%) | 1.98M (+44.53%) | 1.37M (-69.21%) | 4.45M (+100.45%) | 2.22M (-31.69%) | 3.25M (+4.84%) | 3.10M (+46.92%) | 2.11M (-4.52%) | 2.21M (+67.42%) | 1.32M | - | 700K (+14.75%) | 610K (-3.17%) | 630K (+6200.00%) | 10K (-66.67%) | 30K (-50.00%) | 60K (+200.00%) | 20K |
Selling General And Administrative | 4.82M | - | 3.08M (+12.00%) | 2.75M (+1.48%) | 2.71M (-24.93%) | 3.61M (+22.37%) | 2.95M (+18.95%) | 2.48M (+5.98%) | 2.34M (+2.63%) | 2.28M (-5.79%) | 2.42M (+60.26%) | 1.51M (+25.83%) | 1.20M | - | 840K (-11.58%) | 950K (+35.71%) | 700K (+18.64%) | 590K (+84.38%) | 320K (+77.78%) | 180K (+28.57%) | 140K |
Operating Expenses | 11M | - | 7.66M (+13.99%) | 6.72M (+43.59%) | 4.68M (-6.21%) | 4.99M (-32.48%) | 7.39M (+57.23%) | 4.70M (-15.92%) | 5.59M (+3.90%) | 5.38M (+19.03%) | 4.52M (+21.51%) | 3.72M (+47.62%) | 2.52M | - | 1.53M (-1.92%) | 1.56M (+17.29%) | 1.33M (+121.67%) | 600K (+71.43%) | 350K (+45.83%) | 240K (+50.00%) | 160K |
Depreciation And Amortization | 90K | - | - | - | 40K (+33.33%) | 30K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income | |||||||||||||||||||||
Operating Income | -10.80M | - | -7.66M (+13.99%) | -6.72M (+43.59%) | -4.68M (-6.21%) | -4.99M (-32.48%) | -7.39M (+57.23%) | -4.70M (-15.92%) | -5.59M (+3.90%) | -5.38M (+19.03%) | -4.52M (+21.51%) | -3.72M (+47.62%) | -2.52M | - | -1.53M (-1.92%) | -1.56M (+17.29%) | -1.33M (+121.67%) | -600.00K (+71.43%) | -350.00K (+45.83%) | -240.00K (+50.00%) | -160.00K |
Ebit | -10.80M (-63.27%) | -29.40M (+283.81%) | -7.66M (+13.99%) | -6.72M (+43.59%) | -4.68M (-6.21%) | -4.99M (-32.48%) | -7.39M (+57.23%) | -4.70M (-15.92%) | -5.59M (+3.90%) | -5.38M (+19.03%) | -4.52M (+21.51%) | -3.72M (+47.62%) | -2.52M | - | -1.53M (-1.92%) | -1.56M (+17.29%) | -1.33M (+121.67%) | -600.00K (+71.43%) | -350.00K (+45.83%) | -240.00K (+50.00%) | -160.00K |
EBITDA | -10.71M (-63.57%) | -29.40M (+287.86%) | -7.58M (+14.67%) | -6.61M (+42.46%) | -4.64M (-16.09%) | -5.53M (-22.55%) | -7.14M (+63.01%) | -4.38M (-21.65%) | -5.59M (-3.12%) | -5.77M (+35.13%) | -4.27M (+19.61%) | -3.57M (+41.67%) | -2.52M | - | -1.53M (-1.92%) | -1.56M (+17.29%) | -1.33M (+92.75%) | -690.00K (+97.14%) | -350.00K (+133.33%) | -150.00K (-6.25%) | -160.00K |
Other Income / Expenses | |||||||||||||||||||||
Interest Income | 720K | - | 80K (-20.00%) | 100K (-33.33%) | 150K (-21.05%) | 190K (-26.92%) | 260K (-16.13%) | 310K (+14.81%) | 270K (+17.39%) | 230K (+21.05%) | 190K (+46.15%) | 130K (+333.33%) | 30K | - | - | - | - | - | - | - | - |
Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40K (-20.00%) | 50K (0.00%) | 50K (+66.67%) | 30K |
Net Interest Income | 720K | - | 80K (-20.00%) | 100K (-33.33%) | 150K (-21.05%) | 190K (-26.92%) | 260K (-16.13%) | 310K (+14.81%) | 270K (+17.39%) | 230K (+21.05%) | 190K (+46.15%) | 130K (+333.33%) | 30K | - | - | - | - | -40.00K (-20.00%) | -50.00K (0.00%) | -50.00K (+66.67%) | -30.00K |
Other Non Operating Income | 720K | - | 80K (-20.00%) | 100K (-33.33%) | 150K (-85.29%) | 1.02M (+292.31%) | 260K (-16.13%) | 310K (+14.81%) | 270K (-52.63%) | 570K (+200.00%) | 190K (+46.15%) | 130K (+333.33%) | 30K | - | - | - | - | -23.03M (+45960.00%) | -50.00K (+25.00%) | -40.00K (-95.29%) | -850.00K |
Net Income | |||||||||||||||||||||
Income Before Tax | -10.09M | - | -7.58M (+14.67%) | -6.61M (+45.92%) | -4.53M (-5.63%) | -4.80M (-32.77%) | -7.14M (+62.27%) | -4.40M (-17.29%) | -5.32M (+3.30%) | -5.15M (+18.66%) | -4.34M (+20.89%) | -3.59M (+44.18%) | -2.49M | - | -1.53M (-1.92%) | -1.56M (+17.29%) | -1.33M (-94.15%) | -22.75M (+5587.50%) | -400.00K (+90.48%) | -210.00K (-79.41%) | -1.02M |
Income Tax Expense | - | - | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K (0.00%) | 10K | - | - | - | - | - | - | - | - |
Net Income From Continuing Operations | -10.09M (-65.68%) | -29.40M (+287.35%) | -7.59M (+14.65%) | -6.62M (+45.81%) | -4.54M (-5.61%) | -4.81M (-32.73%) | -7.15M (+62.87%) | -4.39M (-16.54%) | -5.26M (+3.34%) | -5.09M (+18.93%) | -4.28M (+19.55%) | -3.58M (+44.35%) | -2.48M | - | -1.54M (-1.28%) | -1.56M (+17.29%) | -1.33M (-94.16%) | -22.76M (+5590.00%) | -400.00K (+90.48%) | -210.00K (-79.41%) | -1.02M |
Net Income | -10.09M (-65.68%) | -29.40M (+287.35%) | -7.59M (+14.65%) | -6.62M (+45.81%) | -4.54M (-5.61%) | -4.81M (-32.73%) | -7.15M (+62.87%) | -4.39M (-16.54%) | -5.26M (+3.34%) | -5.09M (+18.93%) | -4.28M (+19.55%) | -3.58M (+44.35%) | -2.48M | - | -1.54M (-1.28%) | -1.56M (+17.29%) | -1.33M (-94.16%) | -22.76M (+5590.00%) | -400.00K (+90.48%) | -210.00K (-79.41%) | -1.02M |
Comprehensive Income Net Of Tax | -10.04M | - | -7.59M (+15.53%) | -6.57M (+45.03%) | -4.53M (-79.17%) | -21.75M (+207.64%) | -7.07M (+61.78%) | -4.37M (-17.55%) | -5.30M (-65.54%) | -15.38M (+256.84%) | -4.31M (+20.39%) | -3.58M (+44.35%) | -2.48M | - | -1.58M (-1.25%) | -1.60M (+21.21%) | -1.32M (-94.59%) | -24.39M (+5848.78%) | -410.00K (+105.00%) | -200.00K (-80.58%) | -1.03M |